Rationale and efficacy of medical therapy for gastroesophageal reflux disease

Porro, G. Bianchi; Pace, F.

doi:10.1111/j.1365-2796.1993.tb00760.x

Cited by 3 publications

(1 citation statement)

References 71 publications

(22 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On-demand therapy, for which patients only take medication during periods when they are experiencing symptoms, is attractive because it leads to decreased use of medication and, hence, drug-related costs. However, data are only available for patients with NERD and not UD (111)(112)(113)(114)(115)(116). Alternatively, intermittent dosing (a daily two-to four-week course taken when symptoms recur) is a consideration, but this has only been studied in duodenal ulcer patients before the era of H pylori infection (110,116).…”

Section: Please Refer To "Be and Esophageal Cancer -Recommendation 1"mentioning

confidence: 99%

Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool

Zanten

Bradette

Chiba

et al. 2005

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

The present paper is an update to and extension of the previous systematic review on the primary care management of patients with uninvestigated dyspepsia (UD). The original publication of the clinical management tool focused on the initial four- to eight-week assessment of UD. This update is based on new data from systematic reviews and clinical trials relevant to UD. There is now direct clinical evidence supporting a test-and-treat approach in patients with nondominant heartburn dyspepsia symptoms, and head-to-head comparisons show that use of a proton pump inhibitor is superior to the use of H2-receptor antagonists (H2RAs) in the initial treatment of Helicobacter pylori-negative dyspepsia patients. Cisapride is no longer available as a treatment option and evidence for other prokinetic agents is lacking. In patients with long-standing heartburn-dominant (ie, gastroesophageal reflux disease) and nonheartburn-dominant dyspepsia, a once-in-a-lifetime endoscopy is recommended. Endoscopy should also be considered in patients with new-onset dyspepsia that develops after the age of 50 years. Conventional nonsteroidal anti-inflammatory drugs, acetylsalicylic acid and cyclooxygenase-2-selective inhibitors can all cause dyspepsia. If their use cannot be discontinued, cotherapy with either a proton pump inhibitor, misoprostol or high-dose H2RAs is recommended, although the evidence is based on ulcer data and not dyspepsia data. In patients with nonheartburn-dominant dyspepsia, noninvasive testing for H pylori should be performed and treatment given if positive. When starting nonsteroidal anti-inflammatory drugs for a prolonged course, testing and treatment with H2RAs are advised if patients have a history of previous ulcers or ulcer bleeding.

show abstract

Section: Please Refer To "Be and Esophageal Cancer -Recommendation 1"mentioning

confidence: 99%

Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool

Zanten

Bradette

Chiba

et al. 2005

Canadian Journal of Gastroenterology

View full text Add to dashboard Cite

show abstract

Gastroesophageal Reflux and Sinusitis in Asthma

Hamilos

1995

Clinics in Chest Medicine

View full text Add to dashboard Cite

Pharmacological Management of Gastro-Oesophageal Reflux Disease

Klinkenberg‐Knol

Festen

Meuwissen

1995

Drugs

View full text Add to dashboard Cite

Gastro-oesophageal reflux disease (GORD) ranges from episodic symptomatic reflux without oesophagitis to severe oesophageal mucosal damage, such as Barrett's metaplasia or peptic stricture. The multifactorial pathogenesis of GORD prevents medical cure of the disease. GORD is a chronic disease with a high tendency to relapse, requiring a long term treatment strategy in practically all patients. Complete healing of all mucosal lesions is not necessarily the aim of treatment in all patients. In milder forms of reflux disease, symptom relief is the most important goal. Many patients with mild GORD do well on symptomatic self-care with antacids and/or alginate. In addition, lifestyle changes should be advised to all patients: these improve symptoms and enhance the efficacy of therapy. In the acute treatment of GORD the prokinetic drug cisapride has been shown to be effective in relieving symptoms and healing grade I to II oesophagitis. Cisapride decreases symptomatic and endoscopic relapse in patients with mild GORD. Histamine H2-receptor antagonists are effective in relieving reflux symptoms in about 50% of patients, but with regard to healing, H2-antagonists appear to be mainly effective in grades I and II and not in higher grades of oesophagitis. Maintenance treatment with H2-antagonists is mainly symptomatically effective in patients with mild GORD. Proton pump inhibitors (PPIs) provide significantly higher healing rates of reflux oesophagitis than H2-antagonists, even in the more severe cases of oesophagitis and Barrett's ulcers. PPIs are also effective in patients with oesophagitis refractory to treatment with H2-antagonists. PPIs have become the drugs of first choice in healing of all patients with more severe forms of reflux oesophagitis, and increasingly also for patients with milder forms of oesophagitis, certainly those who fail to respond to other drugs. In maintenance treatment of GORD, PPIs are the most effective drugs, offering the possibility of keeping nearly all patients in remission with adjusted doses. Current patient data of up to 5 years indicate the safety of this strategy for this period, but the exact consequences of strong acid inhibition over a longer period still have to be clarified. At present, all but a few patients with GORD can be managed adequately by medical therapy.

show abstract

Rationale and efficacy of medical therapy for gastroesophageal reflux disease

Cited by 3 publications

References 71 publications

Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool

Evidence-Based Recommendations for Short- and Long-Term Management of Uninvestigated Dyspepsia in Primary Care: An Update of the Canadian Dyspepsia Working Group (CanDys) Clinical Management Tool

Gastroesophageal Reflux and Sinusitis in Asthma

Pharmacological Management of Gastro-Oesophageal Reflux Disease

Contact Info

Product

Resources

About